The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
bisbenzimide ethoxide trihydrochloride inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] bisbenzimide ethoxide trihydrochloride results in decreased activity of ABCB11 protein
ABCB1 protein results in increased transport of bisbenzimide ethoxide trihydrochloride ABCB1A protein results in increased transport of bisbenzimide ethoxide trihydrochloride abamectin inhibits the reaction [ABCB1A protein results in increased transport of bisbenzimide ethoxide trihydrochloride]; emamectin inhibits the reaction [ABCB1A protein results in increased transport of bisbenzimide ethoxide trihydrochloride]; Ivermectin inhibits the reaction [ABCB1A protein results in increased transport of bisbenzimide ethoxide trihydrochloride] [zosuquidar trihydrochloride results in decreased activity of ABCB1 protein] which results in decreased export of bisbenzimide ethoxide trihydrochloride; abamectin inhibits the reaction [ABCB1 protein results in increased transport of bisbenzimide ethoxide trihydrochloride]; emamectin inhibits the reaction [ABCB1 protein results in increased transport of bisbenzimide ethoxide trihydrochloride]; Ivermectin inhibits the reaction [ABCB1 protein results in increased transport of bisbenzimide ethoxide trihydrochloride]
abamectin inhibits the reaction [ABCC1 protein results in increased transport of bisbenzimide ethoxide trihydrochloride]; emamectin inhibits the reaction [ABCC1 protein results in increased transport of bisbenzimide ethoxide trihydrochloride]; Ivermectin inhibits the reaction [ABCC1 protein results in increased transport of bisbenzimide ethoxide trihydrochloride]
ABCG2 protein results in decreased abundance of bisbenzimide ethoxide trihydrochloride ABCG2 protein polymorphism results in decreased export of bisbenzimide ethoxide trihydrochloride bisbenzimide ethoxide trihydrochloride results in decreased activity of ABCG2 protein 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]; 3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]; [3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester results in decreased activity of ABCG2 protein] which results in decreased export of bisbenzimide ethoxide trihydrochloride; [bisphenol A results in decreased activity of ABCG2 protein] which results in decreased transport of bisbenzimide ethoxide trihydrochloride; [MLN 8237 affects the activity of ABCG2 protein] which affects the export of bisbenzimide ethoxide trihydrochloride; [MYC protein results in increased expression of ABCG2 protein] which results in increased export of bisbenzimide ethoxide trihydrochloride; Cimetidine inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]; Cyclosporine inhibits the reaction [ABCG2 protein results in increased transport of bisbenzimide ethoxide trihydrochloride]; danofloxacin inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]; Genistein inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]; Genistein promotes the reaction [ABCG2 protein polymorphism results in decreased export of bisbenzimide ethoxide trihydrochloride]; Methotrexate inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]; Nitrofurantoin inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]; Porphyrins inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]; Reserpine inhibits the reaction [ABCG2 protein results in increased transport of bisbenzimide ethoxide trihydrochloride]; Tobacco Smoke Pollution inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]; tryptoquivaline inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]; verlukast inhibits the reaction [ABCG2 protein results in increased transport of bisbenzimide ethoxide trihydrochloride]
Acetylcysteine inhibits the reaction [bosutinib results in increased activity of CASP1 protein]; Acetylcysteine inhibits the reaction [bosutinib results in increased expression of CASP1 mRNA]; bosutinib results in increased activity of and results in increased cleavage of CASP1 protein; Imatinib Mesylate inhibits the reaction [bosutinib results in increased activity of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [bosutinib results in increased activity of and results in increased cleavage of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [bosutinib results in increased expression of CASP1 mRNA]
bosutinib results in decreased expression of CDC25A protein Imatinib Mesylate promotes the reaction [bosutinib results in decreased expression of CDC25A protein]
bosutinib promotes the reaction [CTNNB1 protein binds to CDH1 protein]; CTNNB1 protein promotes the reaction [bosutinib results in increased stability of CDH1 protein]
bosutinib results in increased expression of CDKN1B protein Imatinib Mesylate promotes the reaction [bosutinib results in increased expression of CDKN1B protein]
bosutinib affects the localization of CTNNB1 protein bosutinib results in decreased phosphorylation of CTNNB1 protein bosutinib inhibits the reaction [CTNNB1 protein binds to TCF4 protein]; bosutinib inhibits the reaction [SRC protein results in increased phosphorylation of CTNNB1 protein]; bosutinib promotes the reaction [CTNNB1 protein binds to CDH1 protein]; CTNNB1 protein promotes the reaction [bosutinib results in increased stability of CDH1 protein]
N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [bosutinib results in increased expression of GSDMD mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [bosutinib results in increased expression of GSDMD protein] bosutinib results in increased expression of GSDMD mRNA; bosutinib results in increased expression of GSDMD protein
Acetylcysteine inhibits the reaction [bosutinib results in increased secretion of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [bosutinib results in increased secretion of IL1B protein]
N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [bosutinib results in increased expression of NLRP3 mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [bosutinib results in increased expression of NLRP3 protein] bosutinib results in increased expression of NLRP3 mRNA; bosutinib results in increased expression of NLRP3 protein
[bosutinib co-treated with linsidomine] affects the expression of PARP1 protein; bosutinib affects the reaction [linsidomine results in increased cleavage of PARP1 protein]
bosutinib results in decreased phosphorylation of SRC protein bosutinib inhibits the reaction [SRC protein results in increased phosphorylation of CTNNB1 protein]
Clozapine inhibits the reaction [Bromocriptine results in increased expression of ABCB1 protein]; Clozapine inhibits the reaction [N-n-propylnorapomorphine results in increased expression of ABCB1 protein]; Clozapine inhibits the reaction [Quinpirole results in increased expression of ABCB1 protein] Clozapine results in decreased activity of ABCB1 protein
Clozapine inhibits the reaction [Bromocriptine results in increased activity of ABCB1B promoter]; Clozapine inhibits the reaction [N-n-propylnorapomorphine results in increased activity of ABCB1B promoter]; Clozapine inhibits the reaction [Quinpirole results in increased activity of ABCB1B promoter]
[Clozapine co-treated with 1-(carboxymethylthio)tetradecane] results in increased activity of ACOX1 protein; [Clozapine co-treated with 1-(carboxymethylthio)tetradecane] results in increased expression of ACOX1 mRNA
Clozapine results in decreased expression of ADIPOQ protein Clozapine results in increased expression of ADIPOQ protein Clozapine results in increased expression of ADIPOQ mRNA Berberine inhibits the reaction [Clozapine results in increased expression of ADIPOQ mRNA]
Clozapine inhibits the reaction [Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]]; Clozapine promotes the reaction [Raclopride promotes the reaction [Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]]]
Clozapine results in increased expression of AKT1 mRNA; Clozapine results in increased expression of AKT1 protein Clozapine results in decreased expression of AKT1 mRNA Clozapine results in increased phosphorylation of AKT1 protein
Clozapine results in decreased expression of and results in decreased reduction of ALB protein Clozapine binds to ALB protein [[[stearic acid binds to ALB protein] which affects the susceptibility to Clozapine] which affects the reduction of Cysteine] which affects the activity of ALB protein; [[stearic acid binds to ALB protein] which affects the susceptibility to Clozapine] which affects the reduction of Cysteine; [stearic acid binds to ALB protein] which affects the susceptibility to Clozapine; stearic acid inhibits the reaction [Clozapine binds to ALB protein]
Clozapine inhibits the reaction [Colforsin results in increased expression of ALPP mRNA]; Clozapine inhibits the reaction [Isoproterenol results in increased expression of ALPP mRNA]
Clozapine results in increased expression of BAX mRNA; Clozapine results in increased expression of BAX protein CSF3 protein inhibits the reaction [Clozapine results in increased expression of BAX mRNA] Clozapine results in decreased expression of BAX protein
Clozapine results in decreased expression of BDNF mRNA Clozapine results in increased expression of BDNF mRNA; Clozapine results in increased expression of BDNF protein
Clozapine results in decreased expression of CAMK2A mRNA Clozapine results in increased expression of CAMK2A mRNA Clozapine results in decreased expression of CAMK2A protein
Clozapine results in increased activity of CASP3 protein Palmitic Acid promotes the reaction [Clozapine results in increased activity of CASP3 protein]
Clozapine results in increased activity of CASP7 protein Palmitic Acid promotes the reaction [Clozapine results in increased activity of CASP7 protein]
Clozapine inhibits the reaction [Corticosterone results in increased activity of CAT protein]; Clozapine inhibits the reaction [Lipopolysaccharides inhibits the reaction [Corticosterone results in increased activity of CAT protein]]
Clozapine inhibits the reaction [Dizocilpine Maleate results in decreased expression of CCK mRNA]; Clozapine inhibits the reaction [Dizocilpine Maleate results in decreased expression of CCK protein] Clozapine results in increased expression of CCK mRNA
Berberine inhibits the reaction [Clozapine results in increased expression of CEBPA mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of CEBPA protein] Clozapine results in increased expression of CEBPA mRNA; Clozapine results in increased expression of CEBPA protein
Clozapine analog binds to CHRM1 protein; Clozapine binds to CHRM1 protein Clozapine results in increased expression of CHRM1 protein Clozapine inhibits the reaction [Dextroamphetamine results in decreased expression of CHRM1 protein]
Clozapine results in decreased expression of CNP mRNA Clozapine results in decreased expression of CNP protein Clozapine results in increased expression of CNP mRNA
[tolcapone results in decreased activity of COMT protein] promotes the reaction [Clozapine results in increased abundance of Dopamine] COMT protein affects the susceptibility to Clozapine COMT gene polymorphism results in increased susceptibility to Clozapine
[Clozapine co-treated with 1-(carboxymethylthio)tetradecane] results in increased activity of CPT2 protein; [Clozapine co-treated with 1-(carboxymethylthio)tetradecane] results in increased expression of CPT2 mRNA
Clozapine inhibits the reaction [Haloperidol results in increased phosphorylation of CREB1 protein] Clozapine results in decreased phosphorylation of CREB1 protein
CSF3 protein inhibits the reaction [Clozapine results in increased expression of BAX mRNA]; CSF3 protein inhibits the reaction [Clozapine results in increased expression of BIK mRNA]; CSF3 protein inhibits the reaction [Clozapine results in increased expression of TP53 mRNA]
Clozapine results in increased expression of CTNNB1 protein DRD2 protein affects the reaction [Clozapine results in increased expression of CTNNB1 protein]
Clozapine results in decreased expression of CXCL1 mRNA Clozapine results in decreased secretion of CXCL1 protein belnacasan inhibits the reaction [Clozapine results in increased secretion of CXCL1 protein]
Clozapine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] Clozapine results in decreased activity of CYP1A1 protein CYP1A1 protein results in increased metabolism of Clozapine
CYP1A2 gene SNP results in decreased susceptibility to Clozapine Clozapine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein] CYP1A2 protein results in increased metabolism of Clozapine Clozapine results in increased expression of CYP1A2 mRNA CYP1A2 gene polymorphism affects the metabolism of Clozapine; CYP1A2 protein affects the metabolism of Clozapine; CYP1A2 protein polymorphism affects the metabolism of Clozapine [Ciprofloxacin results in decreased activity of CYP1A2 protein] which results in increased abundance of Clozapine; [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Clozapine; Clozapine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein]; Smoke affects the reaction [CYP1A2 gene polymorphism affects the metabolism of Clozapine]; Smoke promotes the reaction [CYP1A2 protein results in increased metabolism of Clozapine] CYP1A2 gene SNP affects the susceptibility to Clozapine; CYP1A2 protein affects the susceptibility to Clozapine CYP1A2 gene SNP results in increased metabolism of Clozapine; CYP1A2 protein results in increased metabolism of Clozapine CYP1A2 gene SNP results in decreased metabolism of Clozapine
[CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Clozapine CYP2C19 protein results in increased metabolism of Clozapine
CYP2D6 protein affects the metabolism of Clozapine CYP2D6 protein results in increased metabolism of Clozapine [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Clozapine
CYP3A4 protein results in increased metabolism of Clozapine Clozapine results in decreased activity of CYP3A4 protein CYP3A4 protein affects the metabolism of Clozapine [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Clozapine; Clozapine promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Clozapine promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]
Clozapine binds to DRD1 protein Clozapine results in decreased expression of DRD1 mRNA Clozapine analog binds to DRD1 protein DRD1 gene polymorphism affects the susceptibility to Clozapine; DRD1 protein affects the susceptibility to Clozapine
[Clozapine co-treated with DRD2 gene polymorphism] results in increased secretion of PRL protein Clozapine binds to DRD2 protein DRD2 protein affects the susceptibility to Clozapine Clozapine results in decreased expression of DRD2 mRNA Clozapine analog binds to DRD2 protein; Clozapine binds to DRD2 protein [Clozapine binds to and results in decreased activity of DRD2 protein] which results in increased expression of PPP3CA protein; Bromocriptine promotes the reaction [Clozapine results in decreased expression of DRD2 mRNA]; Clozapine binds to and results in decreased activity of DRD2 protein; Clozapine promotes the reaction [Dopamine binds to DRD2 protein]; DRD2 protein affects the reaction [Clozapine results in increased expression of CTNNB1 protein]; DRD2 protein affects the reaction [Clozapine results in increased expression of DVL3 protein]; DRD2 protein affects the reaction [Clozapine results in increased expression of GSK3A protein]; DRD2 protein affects the reaction [Clozapine results in increased expression of GSK3B protein] [Clozapine co-treated with Bromocriptine] results in decreased expression of DRD2 mRNA Clozapine binds to DRD2 protein alternative form DRD2 gene SNP results in increased susceptibility to Clozapine DRD2 gene affects the susceptibility to Clozapine; DRD2 gene polymorphism affects the susceptibility to Clozapine
DRD3 protein affects the susceptibility to Clozapine DRD3 protein affects the reaction [Clozapine results in increased expression of FOSB protein alternative form] DRD3 gene polymorphism results in decreased susceptibility to Clozapine
Clozapine binds to DRD4 protein Clozapine binds to Drd4 protein Clozapine inhibits the reaction [Dopamine results in increased activity of DRD4 protein] Clozapine analog binds to DRD4 protein DRD4 gene polymorphism affects the susceptibility to Clozapine
Clozapine results in increased expression of DVL3 protein DRD2 protein affects the reaction [Clozapine results in increased expression of DVL3 protein]
[Clozapine analog co-treated with Hydrogen Peroxide] results in increased expression of FASLG mRNA; [Clozapine co-treated with Hydrogen Peroxide co-treated with Tretinoin] results in increased expression of FASLG mRNA
Clozapine affects the reaction [Haloperidol results in increased expression of FOS protein]; Cycloserine promotes the reaction [Clozapine results in increased expression of FOS mRNA] Clozapine results in increased expression of FOS protein Clozapine analog results in increased expression of FOS protein; Clozapine results in increased expression of FOS mRNA; Clozapine results in increased expression of FOS protein Clozapine results in decreased expression of FOS protein
Clozapine results in increased expression of FOSB protein alternative form Clozapine results in increased expression of FOSB mRNA; Clozapine results in increased expression of FOSB protein DRD3 protein affects the reaction [Clozapine results in increased expression of FOSB protein alternative form] Clozapine results in decreased expression of FOSB mRNA
Clozapine results in increased expression of GAD1 mRNA Clozapine results in decreased methylation of GAD1 promoter Clozapine promotes the reaction [KMT2A protein binds to GAD1 promoter]; Valproic Acid promotes the reaction [Clozapine results in decreased methylation of GAD1 promoter]
Clozapine results in decreased expression of GNAS mRNA [Cuprizone co-treated with Clozapine] results in decreased expression of GNAS protein Clozapine results in increased expression of GNAS protein
GNB3 gene polymorphism results in decreased susceptibility to Clozapine Clozapine results in increased expression of GNB3 protein GNB3 protein affects the susceptibility to Clozapine GNB3 gene polymorphism results in increased susceptibility to Clozapine
Clozapine results in increased expression of GSK3A protein DRD2 protein affects the reaction [Clozapine results in increased expression of GSK3A protein]
Clozapine results in increased phosphorylation of GSK3B protein Clozapine results in increased expression of GSK3B protein DRD2 protein affects the reaction [Clozapine results in increased expression of GSK3B protein]
GSTM1 protein results in decreased activity of Clozapine Clozapine results in increased expression of GSTM1 mRNA GSTM1 protein results in increased glutathionylation of Clozapine
Clozapine metabolite results in decreased activity of GSTP1 protein; GSTP1 protein results in decreased activity of Clozapine GSTP1 protein affects the metabolism of Clozapine metabolite GSTP1 protein results in increased glutathionylation of Clozapine Clozapine metabolite binds to GSTP1 protein
[Clozapine results in increased activity of HMGCR protein] which results in increased abundance of Cholesterol; [Clozapine results in increased activity of HMGCR protein] which results in increased abundance of Triglycerides Clozapine results in increased expression of HMGCR mRNA
HTR2A gene SNP results in increased susceptibility to Clozapine Clozapine analog binds to HTR2A protein; Clozapine binds to HTR2A protein Clozapine binds to and results in decreased activity of HTR2A protein; Clozapine inhibits the reaction [Ketanserin binds to HTR2A protein] Clozapine results in decreased expression of HTR2A mRNA; Clozapine results in decreased expression of HTR2A protein Clozapine results in decreased activity of HTR2A protein [[Clozapine binds to and results in decreased activity of HTR2A protein] which results in increased phosphorylation of JAK2 protein] which results in increased expression of RGS7 protein; [Clozapine binds to and results in decreased activity of HTR2A protein] which results in increased phosphorylation of JAK2 protein; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [[[Clozapine binds to and results in decreased activity of HTR2A protein] which results in increased phosphorylation of JAK2 protein] which results in increased expression of RGS7 protein]; Clozapine binds to and results in decreased activity of HTR2A protein; Clozapine promotes the reaction [Phencyclidine results in decreased activity of HTR2A protein] HTR2A protein affects the susceptibility to Clozapine Clozapine results in increased expression of HTR2A mRNA
Clozapine binds to HTR2C protein Clozapine results in decreased expression of HTR2C mRNA HTR2C gene polymorphism affects the susceptibility to Clozapine; HTR2C gene SNP affects the susceptibility to Clozapine; HTR2C promoter SNP affects the susceptibility to Clozapine; HTR2C protein affects the susceptibility to Clozapine
Clozapine binds to and results in decreased activity of HTR6 protein [Cuprizone co-treated with Clozapine] results in increased expression of HTR6 protein Clozapine binds to HTR6 protein
Clozapine binds to HTR7 protein [Clozapine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; Clozapine inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]
[[Clozapine binds to and results in decreased activity of HTR2A protein] which results in increased phosphorylation of JAK2 protein] which results in increased expression of RGS7 protein; [Clozapine binds to and results in decreased activity of HTR2A protein] which results in increased phosphorylation of JAK2 protein; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [[[Clozapine binds to and results in decreased activity of HTR2A protein] which results in increased phosphorylation of JAK2 protein] which results in increased expression of RGS7 protein]
Clozapine results in increased expression of KMT2A mRNA Clozapine results in decreased expression of KMT2A mRNA Clozapine promotes the reaction [KMT2A protein binds to GAD1 promoter]
Clozapine results in decreased expression of LPL mRNA; Clozapine results in decreased expression of LPL protein Clozapine results in increased expression of LPL mRNA
Clozapine results in increased lipidation of MAP1LC3B protein [Chloroquine co-treated with Clozapine] results in increased lipidation of MAP1LC3B protein
Clozapine inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK1 protein] Clozapine results in decreased expression of MAPK1 mRNA Clozapine results in decreased phosphorylation of MAPK1 protein
Clozapine results in decreased phosphorylation of MAPK3 protein Clozapine inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK3 protein]
Clozapine results in decreased expression of MFN2 protein PGRMC1 protein inhibits the reaction [Clozapine results in decreased expression of MFN2 protein]
MPO protein affects the susceptibility to Clozapine Clozapine results in increased activity of MPO protein Clozapine promotes the reaction [[MPO protein results in increased metabolism of chlorodimedone] which results in increased abundance of Hypochlorous Acid]; Clozapine promotes the reaction [MPO protein results in increased abundance of Hypochlorous Acid] MPO protein results in increased oxidation of Clozapine
Clozapine results in decreased expression of NGFR protein; Clozapine results in decreased expression of NGFR protein alternative form Clozapine results in decreased expression of NGFR mRNA
NQO2 gene SNP affects the susceptibility to Clozapine Clozapine inhibits the reaction [NQO2 protein results in increased reduction of Vitamin K 3] NQO2 protein results in increased reduction of Clozapine metabolite
Clozapine promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Clozapine promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]
Clozapine results in increased expression of NRG1 mRNA Clozapine affects the expression of NRG1 protein NRG1 protein affects the susceptibility to Clozapine
Clozapine results in increased expression of PDE10A mRNA Clozapine results in increased expression of PDE10A mRNA; Clozapine results in increased expression of PDE10A protein
Clozapine results in decreased expression of PDE4B protein Clozapine results in increased expression of PDE4B mRNA; Clozapine results in increased expression of PDE4B protein
PGRMC1 protein inhibits the reaction [Clozapine results in decreased expression of GLP1R protein]; PGRMC1 protein inhibits the reaction [Clozapine results in decreased expression of MFN2 protein]
Berberine inhibits the reaction [Clozapine results in increased expression of PPARG mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of PPARG protein] Clozapine results in increased expression of PPARG mRNA; Clozapine results in increased expression of PPARG protein
Clozapine inhibits the reaction [Serotonin results in decreased phosphorylation of PPP1R1B protein]; Clozapine inhibits the reaction [Serotonin results in increased phosphorylation of PPP1R1B protein] Clozapine results in increased phosphorylation of PPP1R1B protein
[Clozapine binds to and results in decreased activity of DRD2 protein] which results in increased expression of PPP3CA protein Clozapine results in increased expression of PPP3CA mRNA Clozapine results in decreased expression of PPP3CA mRNA; Clozapine results in decreased expression of PPP3CA protein
Clozapine results in decreased expression of PRKACB mRNA; Clozapine results in decreased expression of PRKACB protein Clozapine results in increased expression of PRKACB mRNA
Clozapine inhibits the reaction [Cyclic AMP binds to PRKAR2A protein] [Cuprizone co-treated with Clozapine] results in decreased expression of PRKAR2A protein Clozapine results in decreased expression of PRKAR2A mRNA; Clozapine results in decreased expression of PRKAR2A protein
Clozapine results in decreased expression of PRKAR2B mRNA; Clozapine results in decreased expression of PRKAR2B protein Clozapine inhibits the reaction [Cyclic AMP binds to PRKAR2B protein]
Clozapine results in increased secretion of PRL protein Clozapine analog results in increased expression of PRL protein [Clozapine co-treated with DRD2 gene polymorphism] results in increased secretion of PRL protein; [Risperidone co-treated with Clozapine] results in increased expression of PRL protein
Clozapine results in decreased expression of RELN mRNA Clozapine results in decreased expression of RELN protein Valproic Acid promotes the reaction [Clozapine results in decreased methylation of RELN promoter]
[[Clozapine binds to and results in decreased activity of HTR2A protein] which results in increased phosphorylation of JAK2 protein] which results in increased expression of RGS7 protein; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [[[Clozapine binds to and results in decreased activity of HTR2A protein] which results in increased phosphorylation of JAK2 protein] which results in increased expression of RGS7 protein] Clozapine results in increased expression of RGS7 mRNA
Clozapine results in decreased activity of SLC1A2 protein Clozapine results in decreased expression of SLC1A2 mRNA; Clozapine results in decreased expression of SLC1A2 protein
[SLC6A4 gene polymorphism results in decreased uptake of Serotonin] which results in decreased susceptibility to Clozapine Clozapine results in increased expression of SLC6A4 SLC6A4 protein affects the susceptibility to Clozapine
Clozapine results in increased expression of SOD1 mRNA Clozapine results in decreased expression of SOD1 protein Clozapine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of SOD1 mRNA]; Clozapine inhibits the reaction [Haloperidol results in decreased expression of SOD1 protein]
Clozapine results in increased expression of SREBF1 mRNA Clozapine results in increased expression of SREBF1 mRNA; Clozapine results in increased expression of SREBF1 protein Berberine inhibits the reaction [Clozapine results in increased expression of SREBF1 mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of SREBF1 protein]
Clozapine inhibits the reaction [25-hydroxycholesterol results in decreased activity of SREBF2 protein]; Clozapine results in increased cleavage of and results in increased activity of SREBF2 protein Clozapine results in increased expression of SREBF2 mRNA
Clozapine inhibits the reaction [Dizocilpine Maleate results in decreased expression of SST mRNA]; Clozapine inhibits the reaction [Dizocilpine Maleate results in decreased expression of SST protein]
Clozapine results in decreased activity of TH protein Ethylmaleimide inhibits the reaction [Clozapine results in decreased expression of TH protein] Clozapine results in increased expression of TH protein Clozapine results in decreased expression of TH mRNA; Clozapine results in decreased expression of TH protein Clozapine results in increased activity of TH protein 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine promotes the reaction [[Clozapine results in increased activity of TH protein] which results in increased metabolism of Dopamine]; [Clozapine results in increased activity of TH protein] which results in increased metabolism of Dopamine
TNF protein affects the susceptibility to Clozapine Clozapine results in increased secretion of TNF protein belnacasan inhibits the reaction [Clozapine results in increased secretion of TNF protein] Clozapine results in increased expression of TNF protein
Clozapine results in decreased expression of TTR mRNA Clozapine results in increased expression of TTR mRNA; Clozapine results in increased expression of TTR protein
[TNF protein co-treated with Levofloxacin] results in increased lipidation of MAP1LC3B protein; TNF protein promotes the reaction [Levofloxacin results in increased expression of MAP1LC3B protein]
[Levofloxacin co-treated with [TNF protein co-treated with IL6 protein co-treated with IL1B protein]] results in increased activity of CASP3 protein; [Levofloxacin co-treated with TNF protein] results in increased expression of ICAM1 protein; [Levofloxacin co-treated with TNF protein] results in increased expression of TNFAIP3 mRNA; [TNF protein co-treated with Levofloxacin] results in increased lipidation of MAP1LC3B protein; TNF protein promotes the reaction [Levofloxacin results in increased expression of MAP1LC3B protein] [Levofloxacin co-treated with TNF protein] results in increased expression of BIRC2 mRNA; [Levofloxacin co-treated with TNF protein] results in increased expression of ICAM1 protein; [Levofloxacin co-treated with TNF protein] results in increased expression of NFKBIA mRNA; [Levofloxacin co-treated with TNF protein] results in increased expression of TNFAIP3 mRNA
Ofloxacin results in decreased activity of ABCB11 protein Ofloxacin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
olanzapine results in decreased activity of ABCB1 protein [[ABCB1A gene mutant form co-treated with ABCB1B gene mutant form] affects the susceptibility to Fluoxetine] which affects the abundance of Olanzapine; [[ABCB1A gene mutant form co-treated with ABCB1B gene mutant form] affects the susceptibility to Fluoxetine] which results in increased uptake of Olanzapine; [ABCB1A gene mutant form co-treated with ABCB1B gene mutant form] results in increased abundance of and results in decreased uptake of Olanzapine
[[ABCB1A gene mutant form co-treated with ABCB1B gene mutant form] affects the susceptibility to Fluoxetine] which affects the abundance of Olanzapine; [[ABCB1A gene mutant form co-treated with ABCB1B gene mutant form] affects the susceptibility to Fluoxetine] which results in increased uptake of Olanzapine; [ABCB1A gene mutant form co-treated with ABCB1B gene mutant form] results in increased abundance of and results in decreased uptake of Olanzapine
Olanzapine results in decreased expression of ACACA mRNA capsazepine inhibits the reaction [Olanzapine results in decreased expression of ACACA mRNA]; Metformin inhibits the reaction [Olanzapine results in decreased expression of ACACA mRNA]; Ruthenium Red inhibits the reaction [Olanzapine results in decreased expression of ACACA mRNA]
[olanzapine co-treated with 1-(carboxymethylthio)tetradecane] results in increased activity of ACOX1 protein; [olanzapine co-treated with 1-(carboxymethylthio)tetradecane] results in increased expression of ACOX1 mRNA
capsazepine inhibits the reaction [Olanzapine results in decreased expression of ADIPOQ protein]; Metformin inhibits the reaction [Olanzapine results in decreased expression of ADIPOQ protein]; Ruthenium Red inhibits the reaction [Olanzapine results in decreased expression of ADIPOQ protein] olanzapine results in increased expression of ADIPOQ mRNA
olanzapine results in increased expression of AGRP protein Metformin inhibits the reaction [Olanzapine results in increased expression of AGRP mRNA]; Ruthenium Red inhibits the reaction [Olanzapine results in increased expression of AGRP mRNA]
Olanzapine results in increased expression of AKT1 mRNA; Olanzapine results in increased expression of AKT1 protein Olanzapine results in decreased expression of AKT1 mRNA capsazepine inhibits the reaction [Olanzapine results in decreased expression of AKT1 mRNA]; Metformin inhibits the reaction [Olanzapine results in decreased expression of AKT1 mRNA]; Ruthenium Red inhibits the reaction [Olanzapine results in decreased expression of AKT1 mRNA] AKT1 gene SNP results in increased susceptibility to olanzapine olanzapine results in increased phosphorylation of AKT1 protein
olanzapine inhibits the reaction [APP protein modified form affects the activity of CAT protein]; olanzapine inhibits the reaction [APP protein modified form results in increased abundance of Reactive Oxygen Species]
olanzapine inhibits the reaction [Methamphetamine results in decreased expression of BCL2 protein] olanzapine results in increased expression of BCL2 mRNA; olanzapine results in increased expression of BCL2 protein
olanzapine results in increased expression of BDNF mRNA; olanzapine results in increased expression of BDNF protein Olanzapine results in increased expression of BDNF mRNA; Olanzapine results in increased expression of BDNF protein
[olanzapine co-treated with 1-(carboxymethylthio)tetradecane] results in decreased expression of CPT2 mRNA; [olanzapine co-treated with 1-(carboxymethylthio)tetradecane] results in increased activity of CPT2 protein; [olanzapine co-treated with 1-(carboxymethylthio)tetradecane] results in increased expression of CPT2 mRNA
olanzapine results in decreased expression of CTNNB1 mRNA Olanzapine results in increased expression of CTNNB1 mRNA Olanzapine inhibits the reaction [Dizocilpine Maleate results in decreased expression of CTNNB1 mRNA]
DRD2 gene SNP results in increased susceptibility to olanzapine; DRD2 intron SNP results in increased susceptibility to olanzapine olanzapine promotes the reaction [Dopamine binds to DRD2 protein] olanzapine results in decreased activity of DRD2 protein olanzapine binds to DRD2 protein olanzapine affects the activity of DRD2 protein
capsazepine inhibits the reaction [Olanzapine results in increased expression of GFAP mRNA]; Metformin inhibits the reaction [Olanzapine results in increased expression of GFAP mRNA]; Ruthenium Red inhibits the reaction [Olanzapine results in increased expression of GFAP mRNA]
capsazepine inhibits the reaction [Olanzapine results in increased expression of GHRL protein]; Metformin inhibits the reaction [Olanzapine results in increased expression of GHRL protein]; Ruthenium Red inhibits the reaction [Olanzapine results in increased expression of GHRL protein]
Olanzapine results in increased expression of GHSR mRNA capsazepine inhibits the reaction [Olanzapine results in increased expression of GHSR mRNA]; Metformin inhibits the reaction [Olanzapine results in increased expression of GHSR mRNA]; Ruthenium Red inhibits the reaction [Olanzapine results in increased expression of GHSR mRNA]
olanzapine results in increased phosphorylation of GSK3B protein Olanzapine inhibits the reaction [Dizocilpine Maleate results in increased expression of GSK3B mRNA] Olanzapine results in decreased expression of GSK3B mRNA
olanzapine results in increased expression of HMGCR mRNA olanzapine results in decreased expression of HMGCR mRNA 1-(carboxymethylthio)tetradecane promotes the reaction [olanzapine results in decreased expression of HMGCR mRNA]; olanzapine promotes the reaction [1-(carboxymethylthio)tetradecane results in decreased expression of HMGCR mRNA]
olanzapine binds to and results in decreased activity of HTR2A protein olanzapine binds to HTR2A protein olanzapine results in decreased activity of HTR2A protein [[olanzapine binds to and results in decreased activity of HTR2A protein] which results in increased phosphorylation of JAK2 protein] which results in increased expression of RGS7 protein; [alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide results in decreased activity of JAK2 protein] inhibits the reaction [olanzapine results in decreased activity of HTR2A protein]; [olanzapine binds to and results in decreased activity of HTR2A protein] which results in increased phosphorylation of JAK2 protein; olanzapine binds to and results in decreased activity of HTR2A protein
HTR2C gene polymorphism results in increased susceptibility to olanzapine olanzapine binds to HTR2C protein HTR2C gene polymorphism affects the susceptibility to Olanzapine; HTR2C gene SNP affects the susceptibility to Olanzapine; HTR2C protein affects the susceptibility to Olanzapine
Olanzapine results in increased expression of IL10 mRNA Olanzapine results in decreased expression of IL10 protein Lithium inhibits the reaction [Olanzapine results in decreased expression of IL10 protein]
Lithium inhibits the reaction [Olanzapine results in increased expression of IL1B mRNA]; Lithium inhibits the reaction [Olanzapine results in increased expression of IL1B protein] Olanzapine results in increased expression of IL1B mRNA; Olanzapine results in increased expression of IL1B protein
capsazepine inhibits the reaction [Olanzapine results in increased expression of IL6 protein]; Lithium inhibits the reaction [Olanzapine results in increased expression of IL6 mRNA]; Lithium inhibits the reaction [Olanzapine results in increased expression of IL6 protein]; Metformin inhibits the reaction [Olanzapine results in increased expression of IL6 protein]; Ruthenium Red inhibits the reaction [Olanzapine results in increased expression of IL6 protein] Olanzapine results in increased expression of IL6 mRNA; Olanzapine results in increased expression of IL6 protein
[[olanzapine binds to and results in decreased activity of HTR2A protein] which results in increased phosphorylation of JAK2 protein] which results in increased expression of RGS7 protein; [alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide results in decreased activity of JAK2 protein] inhibits the reaction [olanzapine results in decreased activity of HTR2A protein]; [alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide results in decreased activity of JAK2 protein] inhibits the reaction [olanzapine results in increased expression of RGS7 mRNA]; [alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide results in decreased activity of JAK2 protein] inhibits the reaction [olanzapine results in increased expression of RGS7 protein]; [olanzapine binds to and results in decreased activity of HTR2A protein] which results in increased phosphorylation of JAK2 protein olanzapine results in increased activity of JAK2 protein
olanzapine results in increased expression of LEP protein Olanzapine results in increased expression of LEP protein capsazepine inhibits the reaction [Olanzapine results in increased expression of LEP protein]; Metformin inhibits the reaction [Olanzapine results in increased expression of LEP protein]; Ruthenium Red inhibits the reaction [Olanzapine results in increased expression of LEP protein]
capsazepine inhibits the reaction [Olanzapine results in increased expression of NFKB1 mRNA]; Ruthenium Red inhibits the reaction [Olanzapine results in increased expression of NFKB1 mRNA]
olanzapine results in decreased expression of NPY mRNA Olanzapine results in increased expression of NPY mRNA capsazepine inhibits the reaction [Olanzapine results in increased expression of NPY mRNA]; Metformin inhibits the reaction [Olanzapine results in increased expression of NPY mRNA]; Ruthenium Red inhibits the reaction [Olanzapine results in increased expression of NPY mRNA] olanzapine results in increased expression of NPY protein
capsazepine inhibits the reaction [Olanzapine results in decreased expression of PIK3R1 mRNA]; Metformin inhibits the reaction [Olanzapine results in decreased expression of PIK3R1 mRNA]; Ruthenium Red inhibits the reaction [Olanzapine results in decreased expression of PIK3R1 mRNA]
olanzapine results in decreased expression of POMC protein Olanzapine results in decreased expression of POMC mRNA capsazepine inhibits the reaction [Olanzapine results in decreased expression of POMC mRNA]; Metformin inhibits the reaction [Olanzapine results in decreased expression of POMC mRNA]; Ruthenium Red inhibits the reaction [Olanzapine results in decreased expression of POMC mRNA]
olanzapine results in decreased expression of PPARGC1A mRNA [olanzapine co-treated with 1-(carboxymethylthio)tetradecane] results in decreased expression of PPARGC1A mRNA; olanzapine promotes the reaction [1-(carboxymethylthio)tetradecane results in decreased expression of PPARGC1A mRNA]
Olanzapine results in increased expression of PRKAG2 mRNA capsazepine inhibits the reaction [Olanzapine results in increased expression of PRKAG2 mRNA]; Metformin inhibits the reaction [Olanzapine results in increased expression of PRKAG2 mRNA]; Ruthenium Red inhibits the reaction [Olanzapine results in increased expression of PRKAG2 mRNA]
[olanzapine co-treated with Fluoxetine] results in increased expression of PRL protein Olanzapine results in increased expression of PRL protein Bromocriptine inhibits the reaction [Olanzapine results in increased expression of PRL protein] olanzapine results in increased secretion of PRL protein olanzapine results in increased expression of PRL protein
[[Olanzapine binds to and results in decreased activity of HTR2A protein] which results in increased phosphorylation of JAK2 protein] which results in increased expression of RGS7 protein; [alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide results in decreased activity of JAK2 protein] inhibits the reaction [Olanzapine results in increased expression of RGS7 mRNA]; [alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide results in decreased activity of JAK2 protein] inhibits the reaction [Olanzapine results in increased expression of RGS7 protein]; Olanzapine promotes the reaction [[STAT3 protein binds to RGS7 promoter] which results in increased expression of RGS7 mRNA]; Olanzapine promotes the reaction [STAT3 protein binds to RGS7 promoter] olanzapine results in increased expression of RGS7 mRNA; olanzapine results in increased expression of RGS7 protein
Olanzapine results in decreased expression of SLC22A5 mRNA; Olanzapine results in decreased expression of SLC22A5 protein Olanzapine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine analog]
olanzapine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of SOD1 mRNA]; olanzapine inhibits the reaction [Haloperidol results in decreased expression of SOD1 protein]; olanzapine inhibits the reaction [Hydrogen Peroxide results in decreased expression of SOD1 mRNA] Olanzapine results in decreased activity of SOD1 protein Dietary Fats promotes the reaction [Olanzapine results in decreased activity of SOD1 protein] olanzapine results in increased expression of SOD1 mRNA
olanzapine promotes the reaction [SREBF1 protein results in increased expression of LDLR mRNA]; olanzapine results in increased activity of and results in increased expression of SREBF1 protein olanzapine results in increased expression of SREBF1 mRNA
olanzapine results in increased cleavage of and results in increased activity of SREBF2 protein [olanzapine co-treated with 1-(carboxymethylthio)tetradecane] results in decreased expression of SREBF2 mRNA
olanzapine promotes the reaction [[STAT3 protein binds to RGS7 promoter] which results in increased expression of RGS7 mRNA]; olanzapine promotes the reaction [STAT3 protein binds to RGS7 promoter]
capsazepine inhibits the reaction [Olanzapine results in increased expression of TNF protein]; Dietary Fats promotes the reaction [Olanzapine results in increased expression of TNF protein]; Lithium inhibits the reaction [Olanzapine results in increased expression of TNF mRNA]; Lithium inhibits the reaction [Olanzapine results in increased expression of TNF protein]; Metformin inhibits the reaction [Olanzapine results in increased expression of TNF protein]; Ruthenium Red inhibits the reaction [Olanzapine results in increased expression of TNF protein] Olanzapine results in increased expression of TNF mRNA; Olanzapine results in increased expression of TNF protein
capsazepine inhibits the reaction [Olanzapine results in increased expression of TRPV1 mRNA]; Ruthenium Red inhibits the reaction [Olanzapine results in increased expression of TRPV1 mRNA]
ponatinib inhibits the reaction [ABL1 protein mutant form results in increased phosphorylation of ABL1 protein mutant form]; ponatinib inhibits the reaction [ABL1 protein mutant form results in increased phosphorylation of CRKL protein]; ponatinib inhibits the reaction [ABL1 protein results in increased phosphorylation of ABL1 protein] ponatinib results in decreased phosphorylation of ABL1 protein; ponatinib results in decreased phosphorylation of ABL1 protein mutant form ponatinib analog results in decreased activity of ABL1 protein; ponatinib analog results in decreased activity of ABL1 protein mutant form; ponatinib results in decreased activity of ABL1 protein; ponatinib results in decreased activity of ABL1 protein mutant form
(+)-JQ1 compound promotes the reaction [ponatinib results in decreased phosphorylation of AKT1 protein]; ponatinib promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of AKT1 protein]
ponatinib results in increased expression of BAX mRNA [gossypol acetic acid results in increased abundance of Gossypol] promotes the reaction [ponatinib results in increased expression of BAX mRNA]
(+)-JQ1 compound promotes the reaction [ponatinib results in decreased expression of BCL2 protein]; ponatinib promotes the reaction [(+)-JQ1 compound results in decreased expression of BCL2 protein] [gossypol acetic acid results in increased abundance of Gossypol] promotes the reaction [ponatinib results in decreased expression of BCL2 mRNA]; ponatinib promotes the reaction [[gossypol acetic acid results in increased abundance of Gossypol] which results in decreased expression of BCL2 mRNA]
(+)-JQ1 compound promotes the reaction [ponatinib results in increased expression of BCL2L11 protein]; ponatinib promotes the reaction [(+)-JQ1 compound results in increased expression of BCL2L11 protein]
ponatinib results in increased expression of CASP1 mRNA Acetylcysteine inhibits the reaction [ponatinib results in increased activity of CASP1 protein]; Acetylcysteine inhibits the reaction [ponatinib results in increased expression of CASP1 mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ponatinib results in increased activity of and results in increased cleavage of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ponatinib results in increased expression of CASP1 mRNA]; ponatinib results in increased activity of and results in increased cleavage of CASP1 protein
[gossypol acetic acid results in increased abundance of Gossypol] promotes the reaction [ponatinib results in increased expression of CASP9 protein]; ponatinib promotes the reaction [[gossypol acetic acid results in increased abundance of Gossypol] which results in increased expression of CASP9 protein]
[gossypol acetic acid results in increased abundance of Gossypol] promotes the reaction [ponatinib results in increased activity of CAT protein]; ponatinib promotes the reaction [[gossypol acetic acid results in increased abundance of Gossypol] which results in increased activity of CAT protein]
(+)-JQ1 compound promotes the reaction [ponatinib results in decreased expression of CDK4 protein]; ponatinib promotes the reaction [(+)-JQ1 compound results in decreased expression of CDK4 protein]
(+)-JQ1 compound promotes the reaction [ponatinib results in decreased expression of CDK6 protein]; ponatinib promotes the reaction [(+)-JQ1 compound results in decreased expression of CDK6 protein]
(+)-JQ1 compound promotes the reaction [ponatinib results in increased expression of CDKN1A protein]; ponatinib promotes the reaction [(+)-JQ1 compound results in increased expression of CDKN1A protein]
ponatinib inhibits the reaction [ABL1 protein mutant form results in increased phosphorylation of CRKL protein] ponatinib results in decreased phosphorylation of CRKL protein
ponatinib analog results in decreased activity of FGFR1 protein; ponatinib results in decreased activity of FGFR1 protein; ponatinib results in decreased activity of FGFR1 protein mutant form ponatinib results in decreased phosphorylation of FGFR1 protein mutant form
ponatinib analog results in decreased activity of FGFR2 protein; ponatinib results in decreased activity of FGFR2 protein; ponatinib results in decreased activity of FGFR2 protein mutant form
ponatinib analog results in decreased activity of FGFR4 protein; ponatinib results in decreased activity of FGFR4 protein ponatinib results in decreased expression of FGFR4 mRNA [gossypol acetic acid results in increased abundance of Gossypol] promotes the reaction [ponatinib results in decreased expression of FGFR4 mRNA]; ponatinib promotes the reaction [[gossypol acetic acid results in increased abundance of Gossypol] which results in decreased expression of FGFR4 mRNA]
ponatinib analog results in decreased activity of FLT3 protein; ponatinib results in decreased activity of FLT3 protein; ponatinib results in decreased activity of FLT3 protein mutant form ponatinib results in decreased phosphorylation of FLT3 protein mutant form ponatinib inhibits the reaction [FLT3 protein mutant form results in increased phosphorylation of FLT3 protein mutant form]
N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ponatinib results in increased expression of GSDMD mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ponatinib results in increased expression of GSDMD protein] ponatinib results in increased expression of GSDMD mRNA; ponatinib results in increased expression of GSDMD protein
ponatinib results in increased secretion of IL1B protein Acetylcysteine inhibits the reaction [ponatinib results in increased secretion of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ponatinib results in increased secretion of IL1B protein]
ponatinib results in decreased activity of KIT protein; ponatinib results in decreased activity of KIT protein mutant form ponatinib results in decreased phosphorylation of KIT protein mutant form
(+)-JQ1 compound promotes the reaction [ponatinib results in decreased phosphorylation of MAPK1 protein]; ponatinib promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of MAPK1 protein]
(+)-JQ1 compound promotes the reaction [ponatinib results in decreased phosphorylation of MAPK3 protein]; ponatinib promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of MAPK3 protein]
(+)-JQ1 compound promotes the reaction [ponatinib results in decreased expression of MYC protein]; ponatinib promotes the reaction [(+)-JQ1 compound results in decreased expression of MYC protein]
ponatinib results in increased expression of NLRP3 mRNA; ponatinib results in increased expression of NLRP3 protein N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ponatinib results in increased expression of NLRP3 mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ponatinib results in increased expression of NLRP3 protein]
(+)-JQ1 compound promotes the reaction [ponatinib results in increased cleavage of PARP1 protein]; ponatinib promotes the reaction [(+)-JQ1 compound results in increased cleavage of PARP1 protein]
ponatinib analog results in decreased activity of PDGFRA protein; ponatinib results in decreased activity of PDGFRA protein; ponatinib results in decreased activity of PDGFRA protein mutant form ponatinib results in decreased phosphorylation of PDGFRA protein mutant form
ponatinib analog results in decreased activity of RET protein; ponatinib results in decreased activity of RET protein; ponatinib results in decreased activity of RET protein mutant form
ponatinib promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of STAT5A protein] ponatinib results in decreased phosphorylation of STAT5A protein
[gossypol acetic acid results in increased abundance of Gossypol] promotes the reaction [ponatinib results in increased expression of TRP53 protein]; ponatinib promotes the reaction [[gossypol acetic acid results in increased abundance of Gossypol] which results in increased expression of TRP53 protein]
[gossypol acetic acid results in increased abundance of Gossypol] promotes the reaction [ponatinib results in decreased expression of VEGFA protein]; ponatinib promotes the reaction [[gossypol acetic acid results in increased abundance of Gossypol] which results in decreased expression of VEGFA protein]
AADAC mRNA affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; bis(4-nitrophenyl)phosphate inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Isoflurophate inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Phenylmethylsulfonyl Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Physostigmine inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Sodium Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin] AADAC protein results in increased hydrolysis of Rifampin
Rifampin results in decreased expression of ABCA1 mRNA; Rifampin results in decreased expression of ABCA1 protein Rifampin results in increased expression of ABCA1 mRNA; Rifampin results in increased expression of ABCA1 protein
Rifampin results in decreased expression of ABCB11 mRNA [Rifampin co-treated with Isoniazid] results in decreased expression of ABCB11 protein Rifampin results in decreased expression of ABCB11 protein tanshinone inhibits the reaction [Rifampin results in decreased expression of ABCB11 mRNA]; tanshinone inhibits the reaction [Rifampin results in decreased expression of ABCB11 protein] Rifampin results in decreased activity of ABCB11 protein [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCB11 protein; Rifampin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Rifampin results in decreased expression of ABCB11 mRNA; Rifampin results in decreased expression of ABCB11 protein
[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein; [Rifampin binds to and results in increased activity of NR1I2 protein] promotes the reaction [ABCB1 protein results in decreased uptake of Doxorubicin]; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 protein; Camptothecin inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of ABCB1 protein]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Resveratrol inhibits the reaction [Rifampin results in increased expression of ABCB1 protein]; Rifampin promotes the reaction [ABCB1 protein results in increased transport of Digoxin]; Rifampin promotes the reaction [NR1I2 protein binds to ABCB1 promoter] Rifampin results in increased expression of ABCB1 mRNA; Rifampin results in increased expression of ABCB1 protein [Rifampin metabolite results in decreased activity of ABCB1A protein] which results in decreased abundance of Adenosine Triphosphate Rifampin affects the activity of ABCB1 protein
ABCC2 protein affects the export of Rifampin [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCC2 protein Rifampin results in increased expression of ABCC2; Rifampin results in increased expression of ABCC2 mRNA; Rifampin results in increased expression of ABCC2 protein [Rifampin co-treated with ABCC2 gene mutant form] results in increased expression of ABCC3 protein
[Rifampin co-treated with ABCC2 gene mutant form] results in increased expression of ABCC3 protein; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCC3 mRNA; Rifampin inhibits the reaction [Decitabine results in increased expression of ABCC3 mRNA] Rifampin results in increased expression of ABCC3 mRNA Rifampin results in increased activity of ABCC3 protein
Rifampin results in increased expression of ABCG2 mRNA; Rifampin results in increased expression of ABCG2 protein Rifampin promotes the reaction [Dextran Sulfate results in decreased expression of ABCG2 mRNA]; Rifampin promotes the reaction [Lipopolysaccharides results in decreased expression of ABCG2 mRNA]
[Rifampin co-treated with Benzo(a)pyrene] results in increased expression of AHR mRNA; [Rifampin co-treated with Monocrotophos] results in decreased expression of AHR mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of AHR protein; NR1I2 protein inhibits the reaction [[Rifampin co-treated with Benzo(a)pyrene] results in increased expression of AHR mRNA] Rifampin results in increased expression of AHR mRNA; Rifampin results in increased expression of AHR protein
Rifampin results in increased expression of AKR1B10 mRNA pazopanib inhibits the reaction [Rifampin results in increased expression of AKR1B10 mRNA]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of AKR1B10 mRNA]
Rifampin results in decreased expression of APOB mRNA ursodoxicoltaurine inhibits the reaction [Rifampin results in decreased expression of APOB mRNA] Rifampin affects the secretion of APOB protein
ATF4 mutant form inhibits the reaction [Rifampin results in increased expression of HSPA5 protein] Rifampin results in increased expression of ATF4 mRNA; Rifampin results in increased expression of ATF4 protein 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of ATF4 mRNA]; 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of ATF4 protein]
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM protein Rifampin results in decreased expression of ATM mRNA
Rifampin results in increased expression of ATP6V0A1 protein [Rotenone co-treated with Rifampin] results in increased expression of ATP6V0A1 protein; Rifampin inhibits the reaction [Rotenone results in decreased expression of ATP6V0A1 mRNA]; Rotenone inhibits the reaction [Rifampin results in increased expression of ATP6V0A1 protein]
[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BAX mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of BAX mRNA; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein] [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in increased expression of BAX protein Rifampin results in decreased expression of BAX protein
Rifampin results in increased expression of BCL2 protein [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein [Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein]
Rifampin results in increased expression of BCL2L1 protein [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BCL2L1 mRNA
Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]]; Rifampin inhibits the reaction [[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of CASP3 protein]; Rifampin inhibits the reaction [Doxorubicin results in increased cleavage of CASP3 protein]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]; Rifampin inhibits the reaction [Staurosporine results in increased cleavage of CASP3 protein]; Rifampin promotes the reaction [Galactosamine results in increased activity of CASP3 protein] [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CASP3 [Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]
Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A protein
[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of CEBPA mRNA; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA protein]
[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of CEBPB mRNA; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB protein]
[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of CEBPD mRNA; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPD mRNA]
Rifampin results in increased expression of CES2 mRNA; Rifampin results in increased expression of CES2 protein Dichlororibofuranosylbenzimidazole inhibits the reaction [Rifampin results in increased expression of CES2 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CES2 mRNA]
Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]]; Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form] Rifampin results in increased expression of CFLAR protein
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CXCL10 mRNA Rifampin affects the expression of CXCL10 protein
Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] Rifampin results in increased activity of CYP1A1 protein Rifampin results in increased expression of CYP1A1 mRNA; Rifampin results in increased expression of CYP1A1 protein [Methylcholanthrene co-treated with Rifampin co-treated with Phenobarbital] results in increased expression of CYP1A1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased activity of CYP1A1 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP1A1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP1A1 protein; [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1A1 mRNA; Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]
[Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1A2 mRNA; Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein] Rifampin results in increased expression of CYP1A2 mRNA; Rifampin results in increased expression of CYP1A2 protein [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP1A2 protein; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 mRNA; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 protein; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 mRNA]; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 protein]
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP1B1 mRNA [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1B1 mRNA
NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP24A1 mRNA]; Rifampin promotes the reaction [NR1I2 protein binds to CYP24A1 promoter] Rifampin results in increased activity of CYP24A1 protein
Rifampin promotes the reaction [[NR1I2 protein binds to NCOA1 protein] which binds to CYP27A1 gene] Rifampin results in increased expression of CYP27A1 mRNA
Rifampin results in increased expression of CYP2A1 mRNA Rifampin results in increased expression of CYP2A13 mRNA Rifampin results in decreased expression of CYP2A13 mRNA
Rifampin results in increased activity of CYP2B6 protein [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2B10 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP2B10 mRNA Rifampin results in increased expression of CYP2B10 mRNA Rifampin results in increased expression of CYP2B6 mRNA; Rifampin results in increased expression of CYP2B6 protein [Rifampin co-treated with Monocrotophos] results in increased activity of CYP2B6 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2B6 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2B6 protein; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2B6 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP2B6 mRNA; Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]]]; Dexamethasone promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; GW 3965 inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of and results in increased activity of CYP2B6 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Rifampin results in increased expression of and results in increased activity of CYP2B6 protein
[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2C23 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2C23 mRNA]
Rifampin results in increased activity of CYP2C19 protein Rifampin results in increased expression of CYP2C29 mRNA [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2C protein Rifampin results in increased expression of CYP2C19 mRNA; Rifampin results in increased expression of CYP2C19 protein Rifampin results in increased expression of and results in increased activity of CYP2C19 protein
[Rifampin binds to NR1I2 protein] which binds to CYP2C8 promoter [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of MCL1 protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in increased expression of BAX protein; Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP2C8 mRNA]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of CYP2C8 mRNA]; Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine] Rifampin results in increased expression of CYP2C8 mRNA; Rifampin results in increased expression of CYP2C8 protein Rifampin results in increased activity of CYP2C8 protein
Rifampin results in increased expression of CYP2D6 mRNA Rifampin results in increased activity of CYP2D6 protein Rifampin results in decreased expression of CYP2D22 mRNA
Rifampin results in increased activity of CYP2E1 protein Rifampin results in decreased expression of CYP2E1 mRNA [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with dendrobine] results in decreased expression of CYP2E1 mRNA; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP2E1 mRNA Rifampin results in increased expression of CYP2E1 mRNA; Rifampin results in increased expression of CYP2E1 protein [Rifampin co-treated with Monocrotophos] results in increased activity of CYP2E1 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2E1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2E1 protein [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Rifampin inhibits the reaction [Isoniazid results in increased expression of CYP2E1 protein]
[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; arsenite inhibits the reaction [Rifampin results in increased expression of and results in increased activity of CYP3A2 protein]; arsenite inhibits the reaction [Rifampin results in increased expression of CYP3A2 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; Rifampin results in increased expression of and results in increased activity of CYP3A2 protein Rifampin affects the activity of CYP3A4 protein Rifampin results in increased expression of CYP3A4; Rifampin results in increased expression of CYP3A4 mRNA; Rifampin results in increased expression of CYP3A4 mRNA alternative form; Rifampin results in increased expression of CYP3A4 protein [[Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein] which results in increased metabolism of and results in increased activity of and results in increased susceptibility to Cobicistat; [Dimethyl Sulfoxide results in increased susceptibility to Rifampin] which results in increased expression of CYP3A4 mRNA; [HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Methylcholanthrene co-treated with Rifampin co-treated with Phenobarbital] results in increased expression of CYP3A4 mRNA; [NR1I2 protein binds to NCOR2 protein] inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; [NR1I2 protein co-treated with Rifampin] results in decreased expression of CYP3A4 mRNA; [PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin binds to CYP3A4 promoter] which results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with Monocrotophos] results in increased activity of CYP3A4 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP3A4 protein; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin results in increased expression of CYP3A4 protein] which results in decreased abundance of Ethinyl Estradiol; [Rifampin results in increased expression of CYP3A4 protein] which results in decreased abundance of Midazolam; [Rifampin results in increased expression of CYP3A4 protein] which results in increased hydroxylation of Testosterone; [Rifampin results in increased expression of NR1I2 protein] which results in increased expression of and results in increased activity of CYP3A4 protein; [RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; AADAC mRNA affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [Rifampin results in increased activity of CYP3A4 protein]; allyl isothiocyanate inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; Arsenic Trioxide inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; Calcitriol promotes the reaction [Rifampin results in increased activity of CYP3A4 protein]; Calcitriol promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased chemical synthesis of 1-hydroxymethylmidazolam]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased chemical synthesis of 4-hydroxymidazolam]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased hydroxylation of Midazolam]; Dexamethasone promotes the reaction [Rifampin results in increased activity of CYP3A4 protein]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Econazole promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Galactosamine inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; GW 3965 inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [Rifampin results in increased activity of CYP3A4 protein]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; lorlatinib inhibits the reaction [Rifampin results in increased activity of CYP3A4 protein]; Metformin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Metformin inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; NR1H3 mutant form inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 gene promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 protein inhibits the reaction [Thapsigargin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR3C1 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; ochratoxin A inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; ochratoxin A inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; oxiconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]]; periodate-oxidized adenosine inhibits the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; PRMT1 protein affects the reaction [[Dimethyl Sulfoxide results in increased susceptibility to Rifampin] which results in increased expression of CYP3A4 mRNA]; PRMT1 protein affects the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; PRMT1 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Rifampin binds to and results in increased activity of CYP3A4 protein; Rifampin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Rifampin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam]; Rifampin inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NCOA1 protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[RXRA protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [Calcitriol results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Rifampin promotes the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Rifampin promotes the reaction [CYP3A4 protein results in increased metabolism of Lidocaine]; Rifampin promotes the reaction [NR1I2 protein binds to CYP3A4 promoter]; Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]; Rifampin results in increased expression of and results in increased activity of CYP3A4 protein; Skatole inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Skatole inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; sodium arsenite inhibits the reaction [Rifampin results in increased expression of and results in increased activity of CYP3A4 protein]; sodium arsenite inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; sulforaphane inhibits the reaction [Rifampin results in increased expression of CYP3A4]; Tetrachlorodibenzodioxin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; Thapsigargin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; trichostatin A affects the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; trichostatin A promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA] CYP3A4 protein results in decreased susceptibility to Rifampin [Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein; Rifampin results in increased activity of CYP3A4 protein Rifampin results in increased expression of CYP3A2 mRNA; Rifampin results in increased expression of CYP3A4 mRNA
[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA; arsenite inhibits the reaction [Rifampin results in increased expression of and results in increased activity of CYP3A23-3A1 protein]; arsenite inhibits the reaction [Rifampin results in increased expression of CYP3A23-3A1 mRNA]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to CYP3A23-3A1 promoter]; Rifampin results in increased expression of and results in increased activity of CYP3A23-3A1 protein; sodium arsenite inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA]
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP7A1 mRNA [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CYP7A1 protein; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of CYP7A1 mRNA] [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CYP7A1 protein
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of DDIT3 mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of DDIT3 mRNA 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of DDIT3 mRNA] Rifampin results in increased expression of DDIT3 mRNA; Rifampin results in increased expression of DDIT3 protein
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of EGR1 mRNA [Rifampin co-treated with NR1I2 protein] results in increased expression of EGR1 mRNA
Rifampin results in increased phosphorylation of EIF2AK3 protein Rifampin results in increased expression of EIF2AK3 mRNA; Rifampin results in increased expression of EIF2AK3 protein 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of EIF2AK3 mRNA]; 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of EIF2AK3 protein]
Rifampin results in increased expression of and results in increased phosphorylation of ERN1 protein Rifampin results in increased expression of ERN1 mRNA
Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]]; Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]]; Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]]; Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]; Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]; Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FASL mRNA Rifampin results in decreased expression of FASLG mRNA; Rifampin results in decreased expression of FASLG protein Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]]; Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]
Rifampin results in increased expression of FASN mRNA Rifampin affects the expression of FASN mRNA pimecrolimus inhibits the reaction [Rifampin results in increased expression of FASN mRNA]
[Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of FGF19 mRNA Rifampin results in increased expression of FGF19 mRNA
[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA; INS protein inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; SGK2 mutant form affects the reaction [Rifampin affects the expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA] Rifampin results in decreased expression of G6PC1 mRNA
4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of GPT protein]; [Rifampin co-treated with Acetaminophen] results in decreased activity of GPT protein Rifampin results in increased activity of GPT protein [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPT protein; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein] [Isoniazid co-treated with Rifampin] results in increased expression of GPT protein; [Rifampin co-treated with Isoniazid] results in increased activity of GPT protein; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased expression of GPT protein]; Rifampin inhibits the reaction [Acetaminophen results in increased expression of GPT protein]
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GPX2 mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of GPX2 mRNA
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]
[Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of GSTA1 mRNA; Ketoconazole inhibits the reaction [Rifampin results in increased expression of GSTA1 mRNA]
[Rifampin co-treated with Monocrotophos] results in increased expression of GSTP1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of GSTP1 protein Rifampin results in increased expression of GSTP1 mRNA; Rifampin results in increased expression of GSTP1 protein
GSTT1 gene polymorphism affects the susceptibility to [Isoniazid co-treated with Rifampin]; GSTT1 gene polymorphism results in increased susceptibility to [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide]
Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]
HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased abundance of Reactive Oxygen Species]; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]
[Rifampin co-treated with NR1I2 protein] results in increased expression of HIF1A mRNA [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HMOX1 mRNA dorsomorphin inhibits the reaction [Rifampin results in increased expression of HMOX1 protein] Rifampin results in increased expression of HMOX1 mRNA; Rifampin results in increased expression of HMOX1 protein [arsenite co-treated with Rifampin] results in increased expression of HMOX1 mRNA
[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of HNF4A mRNA; [Rifampin results in increased activity of NR1I2 protein] inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; allyl isothiocyanate inhibits the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NCOA6 promotes the reaction [Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]]; NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; Rifampin inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [MED1 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA1 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA2 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA6 protein binds to HNF4A protein]; Rifampin promotes the reaction [NR1I2 protein binds to HNF4A protein]; Rifampin promotes the reaction [PPARGC1A protein binds to HNF4A protein]
ATF4 mutant form inhibits the reaction [Rifampin results in increased expression of HSPA5 protein] [Rifampin co-treated with Cobicistat] results in increased expression of HSPA5 mRNA 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of HSPA5 mRNA]; 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of HSPA5 protein] Rifampin results in increased expression of HSPA5 mRNA; Rifampin results in increased expression of HSPA5 protein
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL1B mRNA; Rifampin inhibits the reaction [Rotenone results in increased expression of and results in increased secretion of IL1B protein]; Rifampin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA] Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA]]; Rifampin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA] Rifampin results in decreased expression of IL1B mRNA; Rifampin results in decreased expression of IL1B protein
Rifampin results in decreased expression of IL6 protein Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased expression of IL6 mRNA]]; Rifampin inhibits the reaction [Rotenone results in increased expression of IL6 mRNA] Rifampin results in increased expression of IL6 protein [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of IL6 mRNA
INS protein inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA] Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA protein]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB protein]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPD mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA alternative form]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG protein]
Rifampin results in decreased metabolism of MAP1LC3B protein ATP6V0D1 protein affects the reaction [Rifampin inhibits the reaction [Rotenone results in increased lipidation of MAP1LC3B protein]]; Chloroquine promotes the reaction [Rifampin results in increased lipidation of MAP1LC3B protein]; Rifampin inhibits the reaction [Rotenone results in increased lipidation of MAP1LC3B protein]
Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased phosphorylation of MAPK8 protein]]; Rifampin inhibits the reaction [Rotenone results in increased phosphorylation of MAPK8 protein]
[Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of MCL1 protein
Rifampin promotes the reaction [MED1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [MED1 protein binds to HNF4A protein] Rifampin results in decreased expression of MED1 mRNA
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC gene mutant form] results in increased expression of MKI67 protein
Camptothecin inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; Itraconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Miconazole promotes the reaction [Rifampin results in increased expression of NCOA1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA]; oxiconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; pazopanib inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; pimecrolimus inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; Rifampin inhibits the reaction [NCOA1 protein binds to SLC22A1 promoter]; Rifampin inhibits the reaction [oxiconazole promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Rifampin promotes the reaction [[NCOA1 protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NR1I2 protein binds to NCOA1 protein] which binds to CYP27A1 gene]; Rifampin promotes the reaction [NCOA1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [NCOA1 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]; Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]
NCOA6 promotes the reaction [Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [NCOA6 protein binds to HNF4A protein]
[NR1I2 protein binds to NCOR2 protein] inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Rifampin inhibits the reaction [NCOR2 protein binds to and results in decreased activity of NR1I2 protein]; Rifampin inhibits the reaction [NCOR2 protein binds to NR1I2 protein]; Rifampin inhibits the reaction [NR1I2 protein binds to NCOR2 protein]; Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]; Rifampin promotes the reaction [NR1I2 protein binds to NCOR2 protein]
Rifampin results in increased expression of NFE2L2 protein [tanshinone co-treated with Rifampin] results in increased expression of NFE2L2 mRNA; tanshinone inhibits the reaction [Rifampin results in decreased expression of NFE2L2 mRNA]; tanshinone inhibits the reaction [Rifampin results in decreased expression of NFE2L2 protein] Rifampin results in decreased expression of NFE2L2 mRNA; Rifampin results in decreased expression of NFE2L2 protein Rifampin inhibits the reaction [arsenite results in increased activity of NFE2L2 protein] Rifampin results in decreased activity of NFE2L2 protein
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of NOS2 mRNA Rifampin results in increased expression of NOS2 mRNA
NR1I2 protein affects the susceptibility to Rifampin Rifampin affects the localization of NR1I2 protein Rifampin results in decreased acetylation of NR1I2 protein NR1I2 protein results in increased susceptibility to Rifampin [Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein; Rifampin results in increased activity of NR1I2 protein NR1I2 protein mutant form results in decreased susceptibility to Rifampin 1,5-benzothiazepine analog promotes the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; 7-acetoxy-6,7-dihydro-6-(4-methoxyphenyl)pyrrolo(2,1-d)(1,5)benzothiazepine inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; [[Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein] which results in increased metabolism of and results in increased activity of and results in increased susceptibility to Cobicistat; [fexofenadine co-treated with Rifampin] results in increased activity of NR1I2 protein; [Ketoconazole co-treated with Rifampin] results in increased activity of NR1I2 protein; [Loperamide co-treated with Rifampin] results in increased activity of NR1I2 protein; [NR1I2 protein binds to NCOR2 protein] inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; [NR1I2 protein co-treated with Rifampin] results in decreased expression of CYP3A4 mRNA; [NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA; [NR1I2 protein co-treated with Rifampin] results in decreased expression of SULT1E1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein; [NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin; [Rifampin binds to and results in increased activity of NR1I2 protein] promotes the reaction [ABCB1 protein results in decreased uptake of Doxorubicin]; [Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of FGF19 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of NR1I2 protein; [Rifampin co-treated with NR1I2 protein] results in decreased expression of CYP8B1 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of FOXA1 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of GATA5 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of HDAC5 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of HNF4A mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of SERPINA4 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of STAT5A mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of ANGPTL4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of AQP3 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of BHLHE40 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of BMP4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CCN1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CCR6 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CCR7 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CDKN2B mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP26A1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2B6 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2S1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EDN1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EGR1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EGR2 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EGR4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EPAS1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of HBEGF mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of HEY1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of HIF1A mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP3 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of JUN mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of KLF2 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of KLF5 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of KLF6 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of LEFTY1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of MAFF mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of NPAS1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of NPPB mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of PIP4K2A mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB8 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB9 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINE1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SGK2 protein; [Rifampin co-treated with NR1I2 protein] results in increased expression of SMAD9 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SOCS3 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of UGT1A1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of VEGFD mRNA; [Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein; [Rifampin results in increased activity of NR1I2 protein] inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 protein; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCC3 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP2B6 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of DHCR24 mRNA; [Rifampin results in increased expression of NR1I2 protein] which results in increased expression of and results in increased activity of CYP3A4 protein; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; Camptothecin inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; Camptothecin inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; caraway oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Clove Oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; coriander oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]]]; Doxorubicin inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; enilconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; Epirubicin inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; Fluconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; hydroxyitraconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; INS protein inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; Itraconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Itraconazole promotes the reaction [Rifampin results in increased expression of NR1I2 mRNA]; jasmine oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]]; Ketoconazole inhibits the reaction [Rifampin binds to and results in increased activity of NR1I2 protein]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; lemongrass oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Miconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; NCOA1 protein inhibits the reaction [[NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA]; NCOA6 promotes the reaction [Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]]; NR1I2 gene promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of amprenavir]; NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of Midazolam]; NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of Nelfinavir]; NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of Saquinavir]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of and results in increased activity of CYP2B6 protein]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP2C9 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 protein inhibits the reaction [[Rifampin co-treated with Benzo(a)pyrene] results in increased expression of AHR mRNA]; NR1I2 protein inhibits the reaction [Thapsigargin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of CYP7A1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of GCK protein]; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of SLC2A2 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased abundance of Lipids]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CES2 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP24A1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of GADD45B mRNA]; ochratoxin A inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; Oils, Volatile inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Oils, Volatile promotes the reaction [Rifampin results in increased expression of NR1I2 mRNA]; oxiconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]]; oxiconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; oxiconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; pazopanib inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; pazopanib inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; pimecrolimus inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; pimecrolimus inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; PK 11195 inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; Rifampin binds to and results in increased activity of NR1I2 protein; Rifampin inhibits the reaction [NCOR1 protein binds to and results in decreased activity of NR1I2 protein]; Rifampin inhibits the reaction [NCOR2 protein binds to and results in decreased activity of NR1I2 protein]; Rifampin inhibits the reaction [NCOR2 protein binds to NR1I2 protein]; Rifampin inhibits the reaction [NR1I2 protein binds to NCOR2 protein]; Rifampin inhibits the reaction [oxiconazole promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Rifampin inhibits the reaction [oxiconazole results in increased expression of NR1I2 mRNA]; Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]; Rifampin inhibits the reaction [trichostatin A results in increased acetylation of NR1I2 protein]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NCOA1 protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NR1I2 protein binds to NCOA1 protein] which binds to CYP27A1 gene]; Rifampin promotes the reaction [[RXRA protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [MED1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [NCOA1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]; Rifampin promotes the reaction [NR1I2 protein binds to ABCB1 promoter]; Rifampin promotes the reaction [NR1I2 protein binds to CYP24A1 promoter]; Rifampin promotes the reaction [NR1I2 protein binds to CYP2A6 promoter]; Rifampin promotes the reaction [NR1I2 protein binds to CYP3A4 promoter]; Rifampin promotes the reaction [NR1I2 protein binds to HNF4A protein]; Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]; Rifampin promotes the reaction [NR1I2 protein binds to NCOR2 protein]; Rifampin promotes the reaction [NR1I2 protein binds to SGK2 promoter]; Rifampin promotes the reaction [NR1I2 protein results in decreased expression of SLC22A1 mRNA]; Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA]; sodium arsenite inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; sulforaphane inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; trichostatin A affects the reaction [Rifampin affects the localization of NR1I2 protein]; triptolide inhibits the reaction [Rifampin results in increased activity of NR1I2 protein] Rifampin results in increased expression of NR1I2 mRNA; Rifampin results in increased expression of NR1I2 protein Rifampin results in increased localization of NR1I2 protein [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA; [Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; arsenite inhibits the reaction [Rifampin results in increased localization of NR1I2 protein]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to CYP3A23-3A1 promoter]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]; sodium arsenite inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA] Rifampin binds to NR1I2 gene mutant form [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP1A2 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP2E1 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2B10 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2C protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP3A11 protein; [Rifampin binds to NR1I2 gene mutant form] which results in increased expression of CES2A mRNA; [Rifampin binds to NR1I2 gene mutant form] which results in increased expression of CYP3A11 mRNA; [Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; NR1I2 affects the reaction [Rifampin results in increased activity of CYP3A4 protein]; Rifampin affects the localization of and results in increased activity of NR1I2 protein; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter] [Rifampin binds to NR1I2 protein] which binds to CYP2C8 promoter; Rifampin binds to NR1I2 protein
Rifampin results in increased expression of NR1I3 mRNA [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP1A2 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP2E1 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2B10 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2C protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP3A11 protein Rifampin results in increased expression of NR1I3 mRNA; Rifampin results in increased expression of NR1I3 protein [NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin; [Rifampin co-treated with Monocrotophos] results in increased expression of NR1I3 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of NR1I3 protein
Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]]]; NR3C1 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA] Rifampin results in increased expression of NR3C1 mRNA
Rifampin inhibits the reaction [[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of PARP1 protein]
[Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA] Rifampin results in increased expression of PCK1 mRNA
Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]
[Rifampin co-treated with PPARA protein co-treated with RXRA protein] results in decreased expression of UGDH mRNA [Isoniazid co-treated with Rifampin] results in decreased expression of PPARA protein
[Isoniazid co-treated with Rifampin] results in decreased expression of PPARG protein; [Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of PPARG mRNA; [Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of PPARG mRNA alternative form; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA alternative form]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG protein]; Rifampin results in increased expression of and affects the localization of PPARG protein Rifampin results in increased expression of PPARG mRNA
[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; allyl isothiocyanate inhibits the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [PPARGC1A protein binds to CYP2A6 promoter]; Rifampin promotes the reaction [PPARGC1A protein binds to HNF4A protein]
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC gene mutant form] results in increased expression of MKI67 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CCND1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CHEK2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP1B1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP2A5 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP2B9 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP4A10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP4A14 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP7A1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of DNAJA1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of EGR1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FASL mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO4 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPD1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPE1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL18 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL1B mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of RAD50 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TNFSF10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TRADD mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of XRCC4 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of ANXA5 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BAX mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BCL2L1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CCNG1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CXCL10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP2B10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP3A11 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP3A4 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of DDIT3 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of E2F1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GADD45A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GPX2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM1 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM3 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HMOX1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA1L mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA8 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPB1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of IL6 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of MDM2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of NOS2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of SERPINE1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of UNG mRNA; PRKDC gene mutant form results in increased susceptibility to [Rifampin co-treated with Phenytoin co-treated with Monocrotaline]
PRMT1 protein affects the reaction [[Dimethyl Sulfoxide results in increased susceptibility to Rifampin] which results in increased expression of CYP3A4 mRNA]; PRMT1 protein affects the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; PRMT1 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]
1,5-benzothiazepine analog promotes the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; 7-acetoxy-6,7-dihydro-6-(4-methoxyphenyl)pyrrolo(2,1-d)(1,5)benzothiazepine inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; [Rifampin co-treated with PPARA protein co-treated with RXRA protein] results in decreased expression of UGDH mRNA; [Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein; [RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; allyl isothiocyanate inhibits the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; PK 11195 inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [[RXRA protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA] [Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter] [Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to CYP3A23-3A1 promoter]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of SERPINE1 mRNA [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINE1 mRNA
[Rifampin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SGK2 protein; Rifampin promotes the reaction [NR1I2 protein binds to SGK2 promoter]; SGK2 mutant form affects the reaction [Rifampin affects the expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA] Rifampin results in increased expression of SGK2 mRNA
Rifampin results in decreased expression of SLC10A1 mRNA Rifampin results in decreased expression of SLC10A1 protein [tanshinone co-treated with Rifampin] results in increased expression of SLC10A1 mRNA; [tanshinone co-treated with Rifampin] results in increased expression of SLC10A1 protein; tanshinone inhibits the reaction [Rifampin results in decreased expression of SLC10A1 protein] [Rifampin co-treated with Isoniazid] results in decreased expression of SLC10A1 protein [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of SLC10A1
Rifampin results in decreased expression of SLC22A1 mRNA; Rifampin results in decreased expression of SLC22A1 protein [NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA; NCOA1 protein inhibits the reaction [[NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA]; Rifampin inhibits the reaction [NCOA1 protein binds to SLC22A1 promoter]; Rifampin promotes the reaction [NR1I2 protein results in decreased expression of SLC22A1 mRNA]
NR1I2 protein promotes the reaction [Rifampin results in decreased expression of SLC2A2 protein] Rifampin results in decreased expression of SLC2A2 mRNA; Rifampin results in decreased expression of SLC2A2 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]
Rifampin inhibits the reaction [SLCO1A4 protein results in increased uptake of Digoxin] Rifampin inhibits the reaction [SLCO1A4 protein results in increased uptake of epyrifenacil metabolite] Rifampin results in decreased activity of SLCO1A4 protein
Rifampin inhibits the reaction [SLCO1B3 protein results in increased import of cyanoginosin LR]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased susceptibility to Docetaxel]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of epyrifenacil metabolite]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of estradiol-17 beta-glucuronide]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of fexofenadine]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Hydroxyurea]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Mesalamine]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Sulfobromophthalein]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Ursodeoxycholic Acid metabolite] Rifampin inhibits the reaction [SLCO1B2 protein results in increased uptake of epyrifenacil metabolite] Rifampin results in decreased activity of SLCO1B3 protein Rifampin results in decreased expression of SLCO1B3 mRNA
Rifampin results in decreased activity of SLCO1B1 protein [Rifampin results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Methotrexate
Rifampin results in increased expression of SLCO2B1 mRNA Rifampin results in decreased expression of SLCO2B1 mRNA; Rifampin results in decreased expression of SLCO2B1 protein Rifampin inhibits the reaction [Dextran Sulfate results in increased expression of SLCO2B1 mRNA]; Rifampin inhibits the reaction [Lipopolysaccharides results in increased expression of SLCO2B1 mRNA]; Rifampin inhibits the reaction [SLCO2B1 protein results in increased uptake of Mesalamine]; Rifampin inhibits the reaction [SLCO2B1 protein results in increased uptake of Sulfobromophthalein]
Rifampin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of SNCA protein modified form]; UBE2I affects the reaction [Rifampin results in increased sumoylation of SNCA protein]
[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; allyl isothiocyanate inhibits the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]
[NR1I2 protein co-treated with Rifampin] results in decreased expression of SULT1E1 mRNA; [Rifampin results in increased activity of NR1I2 protein] inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; Rifampin inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]
[Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]
Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]
[Rifampin co-treated with PPARA protein co-treated with RXRA protein] results in decreased expression of UGDH mRNA Rifampin results in increased expression of UGDH mRNA
Rifampin affects the expression of UGT1A1 mRNA Rifampin results in increased expression of UGT1A1 mRNA [Rifampin co-treated with NR1I2 protein] results in increased expression of UGT1A1 mRNA; [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of UGT1A1 mRNA
saracatinib results in decreased activity of CSK protein saracatinib inhibits the reaction [CSK protein results in decreased expression of CYP7A1 mRNA]
saracatinib inhibits the reaction [Calcitriol results in increased expression of CYP24A1 mRNA]; saracatinib inhibits the reaction [lithocholic acid acetate results in increased expression of CYP24A1 mRNA]
saracatinib results in increased expression of CYP7A1 mRNA saracatinib inhibits the reaction [Calcitriol results in decreased expression of CYP7A1 mRNA]; saracatinib inhibits the reaction [CSK protein results in decreased expression of CYP7A1 mRNA]; saracatinib inhibits the reaction [lithocholic acid acetate results in decreased expression of CYP7A1 mRNA]
saracatinib inhibits the reaction [Calcitriol results in increased phosphorylation of VDR protein]; saracatinib inhibits the reaction [lithocholic acid acetate results in increased phosphorylation of VDR protein]
energostim inhibits the reaction [Trifluoperazine results in decreased expression of ACHE protein] Trifluoperazine results in increased activity of ACHE protein
Trifluoperazine inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; Trifluoperazine inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of AKT1 protein]
[PINK1 protein affects the susceptibility to [Trifluoperazine co-treated with Antimycin A co-treated with oligomycin A]] which affects the expression of ATP6V1H mRNA
Trifluoperazine inhibits the reaction [2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethylpropyl)phenol promotes the reaction [gamma-Aminobutyric Acid binds to and results in increased activity of [GABBR1 protein binds to GABBR2 protein]]]
Trifluoperazine inhibits the reaction [2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethylpropyl)phenol promotes the reaction [gamma-Aminobutyric Acid binds to and results in increased activity of [GABBR1 protein binds to GABBR2 protein]]]
[PINK1 protein affects the susceptibility to [Trifluoperazine co-treated with Antimycin A co-treated with oligomycin A]] which affects the expression of LAMP1 mRNA
Trifluoperazine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK1 protein]; Trifluoperazine inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Trifluoperazine inhibits the reaction [Dinoprost results in increased activity of MAPK1 protein]
Trifluoperazine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK3 protein]; Trifluoperazine inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Trifluoperazine inhibits the reaction [Dinoprost results in increased activity of MAPK3 protein]
Trifluoperazine inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MTOR protein] Trifluoperazine analog results in decreased phosphorylation of MTOR protein; Trifluoperazine results in decreased phosphorylation of MTOR protein STON2 protein inhibits the reaction [Trifluoperazine analog results in decreased phosphorylation of MTOR protein]
Trifluoperazine inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MYL9 protein]; Trifluoperazine inhibits the reaction [Ionomycin results in increased phosphorylation of MYL9 protein]
[PINK1 protein affects the susceptibility to [Trifluoperazine co-treated with Antimycin A co-treated with oligomycin A]] which affects the expression of ATP6V1H mRNA; [PINK1 protein affects the susceptibility to [Trifluoperazine co-treated with Antimycin A co-treated with oligomycin A]] which affects the expression of LAMP1 mRNA; [PINK1 protein affects the susceptibility to [Trifluoperazine co-treated with Antimycin A co-treated with oligomycin A]] which affects the expression of TFEB mRNA; PINK1 protein affects the susceptibility to [Trifluoperazine co-treated with Antimycin A co-treated with oligomycin A]; Trifluoperazine affects the reaction [PINK1 protein affects the reaction [[oligomycin A co-treated with Antimycin A] affects the localization of TFEB protein]]
Trifluoperazine analog results in decreased expression of STON2 protein STON2 protein inhibits the reaction [Trifluoperazine analog results in decreased phosphorylation of MTOR protein]
[PINK1 protein affects the susceptibility to [Trifluoperazine co-treated with Antimycin A co-treated with oligomycin A]] which affects the expression of TFEB mRNA; Trifluoperazine affects the reaction [PINK1 protein affects the reaction [[oligomycin A co-treated with Antimycin A] affects the localization of TFEB protein]]
UGT1A4 protein results in increased glucuronidation of Trifluoperazine Finasteride inhibits the reaction [UGT1A4 protein results in increased glucuronidation of Trifluoperazine]; hecogenin inhibits the reaction [UGT1A4 protein results in increased glucuronidation of Trifluoperazine]; licochalcone A inhibits the reaction [Trifluoperazine results in increased activity of UGT1A4 protein]; Trifluoperazine inhibits the reaction [UGT1A4 protein results in increased glucuronidation of afloqualone]
browse the term
